Previous 10 | Next 10 |
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results PR Newswire -- Achieved $204.2 million in AYVAKIT ® /AYVAKYT ® (avapritinib) net product revenues in 2023, including $71.0 million in the fourth quarter -- -- Anti...
Propanc Biopharma Inc (PPCB) is expected to report for Q2 2024 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 Arch Resources Inc. Class A (ARCH) is expected to report $6.9 for Q4 2023 Bloom Energy Corporation Class A (BE) is expected to report $-0.0...
2024-02-14 15:30:47 ET Summary Cogent Biosciences, Inc. has entered into a securities purchase agreement for a private investment in public equity financing, expected to raise approximately $225 million. The financing was led by Commodore Capital and a large investment management ...
2024-02-14 14:07:39 ET More on Blueprint Medicines Blueprint Medicines: Looking Toppy Barron’s cites cancer and weight loss plays for biotech M&A Seeking Alpha’s Quant Rating on Blueprint Medicines Historical earnings data for Blueprint Medi...
2024-02-13 10:15:02 ET Wells Fargo analyst issues MARKET OUTPERFORM recommendation for BPMC on February 13, 2024 10:00AM ET. The previous analyst recommendation was Market Outperform. BPMC was trading at $74.52 at issue of the analyst recommendation. The overall analyst ...
2024-02-04 17:16:46 ET More on Alnylam Pharmaceuticals, Fusion Pharmaceuticals, etc. Merus Stock: Rally Seems Overdone Alnylam's Huge Opportunity Merus: (Maybe) Building A Better Bispecific Regeneron eyes Wegovy combo to improve quality of weight loss ...
Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024 PR Newswire CAMBRIDGE, Mass. , Feb. 1, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live co...
2024-01-28 06:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-17 07:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-09 11:40:35 ET More on Madrigal, Viking, etc. Madrigal Pharmaceuticals: A Deeper Look At A Looming NASH Play Viking: Results From 2 Clinical Trials Of Weight Loss Drug Ahead, Other Catalysts On Tap Madrigal Pharmaceuticals: Preparing For Resmetirom's Commerci...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting PR Newswire -- Updated Phase 1 dose escalation data show that BLU...
WILMINGTON, Del., May 20, 2024 (GLOBE NEWSWIRE) -- The law firm of Andrews & Springer LLC, a boutique securities class action law firm focu...
WILMINGTON, Del., May 20, 2024 (GLOBE NEWSWIRE) -- The law firm of Andrews & Springer LLC , a boutique securities class action law firm focused on representing shareholders, is investigating potential securities violations and breach of fiduciary duty claims against Blueprint Medicin...